Physician profile
Ammar Dulli
NPI 1487874145
$812.52
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $246 · 2021: $277 · 2022: $95.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $554.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.80 | 2019-2020 | |
| Amgen INC. | $35.16 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $29.76 | 2021-2022 | |
| United Therapeutics Corporation | $25.41 | 2020 | |
| Eisai INC. | $24.02 | 2019 | |
| Merck Sharp & Dohme LLC | $15.21 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.77 | 2019 | |
| Pfizer INC. | $13.46 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Dulli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.